Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications

Clinical Therapeutics

Volumn 30, Issue PART 1, 2008, Pages 1038-1050

  Dormuth, Colin R ^a,b   Maclure, Malcolm ^c,d   Glynn, Robert J ^a,c   Neumann, Peter ^e   Brookhart, Alan M ^a   Schneeweiss, Sebastian ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF VICTORIA   (Canada)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

asthma; COPD; drug benefit plans; health care utilization; health outcomes; health services research; inhaled medications; pharmacoeconomics

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; XANTHINE DERIVATIVE;

AGED; ARTICLE; ASTHMA; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; EMERGENCY HEALTH SERVICE; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCOME; INHALER; LONG TERM CARE; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; AGED, 80 AND OVER; ASTHMA; CANADA; CHOLINERGIC ANTAGONISTS; COHORT STUDIES; DEDUCTIBLES AND COINSURANCE; DRUG UTILIZATION; EMERGENCY SERVICE, HOSPITAL; EMPHYSEMA; FEMALE; GLUCOCORTICOIDS; HEALTH POLICY; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; LUNG DISEASES; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATE HEALTH PLANS;

EID: 47149117452     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.06.003     Document Type: Article

References (32)

1. Maclure M. Drug insurance utilization management policies and "reference pricing": An illustrated commentary on the article by Vittorio Maio and colleagues. Milbank Q. 83 (2005) 131-147
2. Soumerai S., Ross-Degnan D., Avorn J., et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 325 (1991) 1072-1077
3. Tamblyn R., Laprise R., Hanley J., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 285 (2001) 421-429
4. Kozyrskyj A., Mustard C., Cheang M., and Simons F. Income-based drug benefit policy: Impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. CMAJ. 165 (2001) 897-902
5. Schneeweiss S., Walker A., Glynn R., et al. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 346 (2002) 822-829
6. Grootendorst P., Dolovich L., O'Brien B., et al. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. CMAJ. 165 (2001) 1011-1019
7. Schneeweiss S., Soumerai S., Maclure M., et al. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 74 (2003) 388-400
8. Marshall J., Grootendorst P., O'Brien B., et al. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ. 166 (2002) 1655-1662
9. Schneeweiss S., Maclure M., Carleton B., et al. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: Direct comparison of randomised and observational evaluations. BMJ. 328 (2004) 560
10. Huskamp H., Deverka P., Epstein A., et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 349 (2003) 2224-2232
11. Motheral B., and Fairman K. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 39 (2001) 1293-1304
12. Briesacher B., Kamal-Bahl S., Hochberg M., et al. Three-tieredcopayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Arch Intern Med. 164 (2004) 1679-1684
13. Salpeter S., Buckley N., and Salpeter E. Meta-analysis: Anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPDI [published correction appears in J Gen Intern Med. 2006;21:1131]. J Gen Intern Med. 21 (2006) 1011-1019
14. Appleton S., Poole P., Smith B., et al. Long-acting β2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3 (2006) CD001104
15. Alsaeedi A., Sin D., and McAlister F. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials. Am J Med. 113 (2002) 59-65
16. van Grunsven P., van Schayck C., Derenne J., et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A meta-analysis. Thorax. 54 (1999) 7-14
17. Dormuth C., Glynn R., Neumann P., et al. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 28 (2006) 964-978
18. World Health Organization (WHO). International Classification of Diseases. 9th Revision. Clinical Modification (2003). http://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD9-CM/2003/ [CDC Web site]
19. World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems. 2nd ed (2004), WHO, Geneva, Switzerland 10th rev.
20. Williams J., and Young W. Inventory of studies on the accuracy of Canadian health administrative databases. Technical report (1996), Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
21. Fowles J., Lawthers A., Weiner J., et al. Agreement between physicians' office records and Medicare Part B claims data. Health Care Financ Rev. 16 (1995) 189-199
22. Romano P., and Mark D. Bias in the coding of hospital discharge data and its implications for quality assessment. Med Care. 32 (1994) 81-90
23. Glynn R., Monane M., Gurwitz J., et al. Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. Am J Epidemiol. 149 (1999) 541-549
24. Fisher E., Whaley F., Krushat W., et al. The accuracy of Medicare's hospital claims data: Progress has been made but problems remain. Am J Public Health. 82 (1992) 243-248
25. Pharmacare. Your Fair PharmaCare coverage [Pharmacare Web site]. www.healthservices.gov.bc.ca/pharme/plani/planiinfo.html#M Accessed April 14, 2008
26. Truitt T., Witko J., and Halpern M. Levalbuterol compared to racemic albuterol: Efficacy and outcomes in patients hospitalized with COPD or asthma. Chest. 123 (2003) 128-135
27. Liang K.-Y., and Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 73 (1986) 13-22
28. Kennedy P. A Guide to Econometrics. 4th ed (1988), MIT Press, Cambridge, Mass 123-125
29. Warburton R. Takeup of incometested health-care premium subsidies: Evidence and remedies for British Columbia. Can Tax J. 53 (2005) 1-28
30. Romano P., Roos L., and Jollis J. Adapting a clinical comorbidity index for use with ICD-9 CM administrative data: Differing perspectives. J Clin Epidemiol. 46 (1993) 1075-1079
31. Schneeweiss S., Maclure M., and Soumerai S. Prescription duration after drug copay changes in the elderly: Methodological aspects. J Am Geriatr Soc. 50 (2002) 521-525
32. Choudhry N., Avorn J., Antman E., et al. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff. 26 (2007) 186-194